Sign up
LTRN

Lantern Pharma Inc (NASDAQ: LTRN)

Healthcare · Biotechnology

$0.33−0.04 (−9.86%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. LTRN fell 9.86% in the Nov 18 session to $0.33. The borrow fee is 1.82%. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

Momentum—

—

Trend—

—

Short interest—

—

LTRN price chart

Price $0.33 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$0.36Nov 18, 2026 session
Previous close
$0.37Nov 17, 2026 close
Day range
$0.32 – $0.38Nov 18, 2026 session
52-week range—
Volume
307.80KNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

LTRN · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

— · Quantellect signals not available

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.38−$0.37—
Q2 2026−$0.38−$0.57—
Q1 2026−$0.36−$0.30—
Annual 2025—−$1.57—
Q3 2025—−$0.39—
Q2 2025—−$0.40—
Q1 2025—−$0.42—
Annual 2024−$0.51−$1.93—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All LTRN news →

Company profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central

CEO
Mr. Panna Sharma
Headquarters
Dallas, TX, United States
Employees
16
IPO date
Jun 11, 2020
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.